Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the <scp>EUSTAR</scp> database
Our findings reveal a significant evolution in clinical practice. However, continued disease progression emphasizes the need for more effective therapeutic approaches.
Authors
- G. De Luca
- ANA MARIA GHEORGHIU
- R. Bečvář
- M Truchetet
- L. Ananieva
- N. Hunzelmann
- Patricia Carreira
- Vanessa Smith
- Giovanna Cuomo
- Corrado Campochiaro
- Anna‐Maria Hoffmann‐Vold
- Marco Matucci‐Cerinic
- Eric Hachulla
- Daniel E. Furst
- Madelon Vonk
- Francesco Del Galdo
- Vera Ortiz‐Santamaria
- EUSTAR collaborators
Institutions
- Hebron University (PS)
- Oslo University Hospital (NO)
- Radboud University Nijmegen (NL)
- Université de Bordeaux (FR)
- Vita-Salute San Raffaele University (IT)
- Inserm (FR)
- University of California, Los Angeles (US)
- University of Zurich (CH)
- Charles University (CZ)
- Université de Lille (FR)
- Leeds Teaching Hospitals NHS Trust (GB)
- Ghent University Hospital (BE)
- Radboud University Medical Center (NL)
- University of California System (US)
- Centre Hospitalier Universitaire de Lille (FR)
- Emergency University (US)
- University Hospital of Zurich (CH)
- Hospital Universitario 12 De Octubre (ES)
- Federico II University Hospital (IT)
- Association of Rheumatologists of Russia (RU)
- Vall d'Hebron Hospital Universitari (ES)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1002/art.70043
- Citations
- 1
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 36.00